XML 41 R30.htm IDEA: XBRL DOCUMENT
v3.25.2

REVENUE (Tables) | 9 Months Ended
--- | ---
Jul. 31, 2025
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended July 31,
| 2025 |  | 2024
| Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total |  | Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 316 |  |  | $ | 274 |  |  | $ | 93 |  |  | $ | 683 |  |  | $ | 268 |  |  | $ | 267 |  |  | $ | 91 |  |  | $ | 626 |
Europe | 201 |  |  | 212 |  |  | 79 |  |  | 492 |  |  | 177 |  |  | 184 |  |  | 71 |  |  | 432 |
Asia Pacific | 153 |  |  | 258 |  |  | 152 |  |  | 563 |  |  | 140 |  |  | 240 |  |  | 140 |  |  | 520 |
Total | $ | 670 |  |  | $ | 744 |  |  | $ | 324 |  |  | $ | 1,738 |  |  | $ | 585 |  |  | $ | 691 |  |  | $ | 302 |  |  | $ | 1,578 |
| Nine Months Ended July 31,
| 2025 |  | 2024
| Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total |  | Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 953 |  |  | $ | 805 |  |  | $ | 272 |  |  | $ | 2,030 |  |  | $ | 841 |  |  | $ | 779 |  |  | $ | 273 |  |  | $ | 1,893 |
Europe | 568 |  |  | 594 |  |  | 235 |  |  | 1,397 |  |  | 537 |  |  | 551 |  |  | 228 |  |  | 1,316 |
Asia Pacific | 450 |  |  | 754 |  |  | 456 |  |  | 1,660 |  |  | 431 |  |  | 711 |  |  | 458 |  |  | 1,600 |
Total | $ | 1,971 |  |  | $ | 2,153 |  |  | $ | 963 |  |  | $ | 5,087 |  |  | $ | 1,809 |  |  | $ | 2,041 |  |  | $ | 959 |  |  | $ | 4,809 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Nine Months Ended
| July 31, |  | July 31,
| 2025 |  | 2024 |  | 2025 |  | 2024
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 629 |  |  | $ | 540 |  |  | $ | 1,817 |  |  | $ | 1,647 |
Diagnostics and Clinical | 258 |  |  | 242 |  |  | 753 |  |  | 709 |
Academic and Government | 132 |  |  | 128 |  |  | 404 |  |  | 417 |
Chemicals and Advanced Materials | 399 |  |  | 356 |  |  | 1,147 |  |  | 1,110 |
Food | 157 |  |  | 144 |  |  | 472 |  |  | 440 |
Environmental and Forensics | 163 |  |  | 168 |  |  | 494 |  |  | 486 |
Total | $ | 1,738 |  |  | $ | 1,578 |  |  | $ | 5,087 |  |  | $ | 4,809 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 599 |  |  | $ | 556 |  |  | $ | 1,774 |  |  | $ | 1,734 |
Non-instrumentation and other | 1,139 |  |  | 1,022 |  |  | 3,313 |  |  | 3,075 |
Total | $ | 1,738 |  |  | $ | 1,578 |  |  | $ | 5,087 |  |  | $ | 4,809 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the changes in the balances during the nine months ended July 31, 2025:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2024 |  | $ | 701 |
Net revenue deferred in the period |  | 506 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (429) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 13 |
Currency translation and other adjustments |  | 9 |
Ending balance as of July 31, 2025 |  | $ | 800 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration